Xuejun Liu

591 total citations
22 papers, 344 citations indexed

About

Xuejun Liu is a scholar working on Transportation, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Xuejun Liu has authored 22 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Transportation, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in Xuejun Liu's work include Urban Transport and Accessibility (5 papers), Diabetes Treatment and Management (4 papers) and Pancreatic function and diabetes (3 papers). Xuejun Liu is often cited by papers focused on Urban Transport and Accessibility (5 papers), Diabetes Treatment and Management (4 papers) and Pancreatic function and diabetes (3 papers). Xuejun Liu collaborates with scholars based in China, United States and Germany. Xuejun Liu's co-authors include Frank LaCreta, David W. Boulton, Sreeneeranj Kasichayanula, Steven C. Griffen, Marc Pfister, Mayumi Hasegawa, W. Zhang, Ming Chang, Qisheng Pan and T. Li and has published in prestigious journals such as Annals of Oncology, Urban Studies and Diabetes Obesity and Metabolism.

In The Last Decade

Xuejun Liu

20 papers receiving 330 citations

Peers

Xuejun Liu
J Freiman United States
Devin Abrahami Canada
M. France United Kingdom
Nils Ekström Sweden
Mike M. Nguyen United States
Takayasu Taira Japan
Camino Rodrı́guez-Villar Spain
Peter Alperin United States
Euridiki Drogari Greece
Guillermo González-Gálvez Mexico
J Freiman United States
Xuejun Liu
Citations per year, relative to Xuejun Liu Xuejun Liu (= 1×) peers J Freiman

Countries citing papers authored by Xuejun Liu

Since Specialization
Citations

This map shows the geographic impact of Xuejun Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuejun Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuejun Liu more than expected).

Fields of papers citing papers by Xuejun Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuejun Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuejun Liu. The network helps show where Xuejun Liu may publish in the future.

Co-authorship network of co-authors of Xuejun Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xuejun Liu. A scholar is included among the top collaborators of Xuejun Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuejun Liu. Xuejun Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cohen, Alexander T., Amol D. Dhamane, Xuejun Liu, et al.. (2024). Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism. Journal of the National Comprehensive Cancer Network. 22(6). 397–403. 1 indexed citations
2.
Liu, Xuejun, Daniela R. Junqueira, Kyle Fahrbach, et al.. (2024). Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis. Seminars in Thrombosis and Hemostasis. 50(3). 328–341. 8 indexed citations
3.
4.
Liu, Xuejun, Jenny Jiang, Danshi Li, et al.. (2023). Antiplatelet Treatment Patterns and Outcomes for Secondary Stroke Prevention in the United Kingdom. Cardiology and Therapy. 12(4). 675–687. 2 indexed citations
5.
Dhamane, Amol D., et al.. (2023). Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer. Thrombosis Research. 224. 52–59. 1 indexed citations
6.
7.
Tolaney, Sara M., Guy Jérusalem, Roberto Salgado, et al.. (2020). 133TiP A phase II trial of nivolumab + palbociclib + anastrozole in postmenopausal women with ER+/HER2– primary breast cancer: CheckMate 7A8. Annals of Oncology. 31. S60–S60. 2 indexed citations
8.
Liu, Yanying, Xuejun Liu, Wenhao Yang, et al.. (2019). Association between cumulative serum urate and development of diabetes type II: the Kailuan Study. Clinical Rheumatology. 39(2). 339–346. 1 indexed citations
9.
Liu, Xuejun, et al.. (2018). Analysing the changes of employment subcentres: A comparison study of Houston and Dallas. Urban Studies. 56(12). 2532–2548. 13 indexed citations
10.
Cheng, Liang, Xuejun Liu, Song Chen, et al.. (2018). Spatio-temporal analysis of educational convenience in ethnic mountainous areas with road network constraints—A case study of Yunnan Province, China. Applied Geography. 100. 39–54. 6 indexed citations
11.
Liu, Xuejun, et al.. (2017). Evaluating medical convenience in ethnic minority areas of Southwest China via road network vulnerability: a case study for Dehong autonomous prefecture. International Journal for Equity in Health. 16(1). 206–206. 4 indexed citations
12.
Liu, Xuejun, et al.. (2017). Comparative analysis of cluster versus conventional immunotherapy in patients with allergic rhinitis. Experimental and Therapeutic Medicine. 13(2). 717–722. 4 indexed citations
13.
Li, Xiaofei, et al.. (2012). Hypophosphatasia. Skeletal Radiology. 42(2). 317–318. 1 indexed citations
14.
Kasichayanula, Sreeneeranj, Xuejun Liu, Steven C. Griffen, Frank LaCreta, & David W. Boulton. (2012). Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obesity and Metabolism. 15(3). 280–283. 55 indexed citations
15.
Kasichayanula, Sreeneeranj, Xuejun Liu, W. Zhang, et al.. (2011). Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obesity and Metabolism. 13(8). 770–773. 39 indexed citations
16.
Kasichayanula, Sreeneeranj, Ming Chang, Mayumi Hasegawa, et al.. (2011). Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 13(4). 357–365. 100 indexed citations
17.
Dong, Zheng, et al.. (2010). Diagnostic value of detection of TRUST and TPPA in CSF on neurosyphilis. Chinese Journal of Neuromedicine. 9(8). 841–843. 1 indexed citations
18.
Kasichayanula, Sreeneeranj, Xuejun Liu, W. Zhang, et al.. (2010). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obesity and Metabolism. 13(1). 47–54. 76 indexed citations
19.
Liu, Xuejun, Albert Park, & Yaohui Zhao. (2010). Explaining Rising Returns to Education in Urban China in the 1990s. SSRN Electronic Journal. 12 indexed citations
20.
Liu, Xuejun. (2008). INFLUENCE OF IMPURITY TYPES AND CONTENT ON THE BULK DENSITY OF WHEAT.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Freiman Breakdown of academic impact, for papers by Devin Abrahami Breakdown of academic impact, for papers by M. France Breakdown of academic impact, for papers by Nils Ekström Breakdown of academic impact, for papers by Mike M. Nguyen Breakdown of academic impact, for papers by Takayasu Taira Breakdown of academic impact, for papers by Camino Rodrı́guez-Villar Breakdown of academic impact, for papers by Peter Alperin Breakdown of academic impact, for papers by Euridiki Drogari Breakdown of academic impact, for papers by Guillermo González-Gálvez
Rankless by CCL
2026